Brazil's Pharmaceutical Market Value Will Approach $48B By 2020, Says GlobalData

• Brazilian pharmaceutical market will expand in value from $29.4B in 2014 to approximately $47.9B by 2020
• ‘Brazil is now one of the most attractive and promising pharmaceutical markets in the world,’ says director

The Brazilian pharmaceutical market will expand in value from $29.4B in 2014 to reach approximately $47.9B by 2020, representing a strong Compound Annual Growth Rate (CAGR) of 8.5%, according to research and consulting firm GlobalData.

The company’s latest report^* states that Brazil’s increasingly elderly population, which will lead to a rising incidence of chronic and lifestyle-associated diseases, as well as the country’s robust investment in healthcare, will be key drivers of market growth during the forecast period.

Joshua Owide, GlobalData’s Director of Healthcare Industry Dynamics, says that the Brazilian pharmaceutical industry continues to prosper, primarily thanks to the country’s economic policies and reforms.

Owide comments: “Brazil has emerged as a global manufacturing hub for pharmaceutical and biotechnology companies, with countries such as India investing heavily in the manufacturing sector after former Brazilian health minister, José Serra, invited investment from generic companies.

“As a consequence, Brazil is now one of the most attractive and promising pharmaceutical markets in the world. Indeed, its pharmaceutical market value has increased considerably over the past six years, having more than doubled from $14.1B in 2008.”

GlobalData’s report also states that Brazil’s market for generic drugs is witnessing rapid growth, with almost all of the country’s generics procured by the public healthcare system.

Owide continues: “Government initiatives, such as the People’s Pharmacy program (Farmácia Popular), have been responsible for the increased usage and availability of generics, further boosted by the announcement of $34B (BRL106 billion) investment in the Brazilian healthcare sector in 2014.

“According to the US Department of Commerce, approximately 80% of pharmaceutical companies in Brazil are domestic, and this number has been increasing since the Generic Law was introduced in 1999. However, Multinational Companies (MNC) currently generate higher revenues than domestic companies.”

The leading MNCs operating in the Brazilian pharmaceutical market are Pfizer, Novartis and Roche, while the major domestic companies are Hypermarcas and EMS Sigma Pharma, according to GlobalData.

This report provides information on the healthcare, regulatory, and reimbursement landscape in Brazil. It includes an overview of the pharmaceutical and medical device sectors, including market size, segmentation, and key drivers and barriers, as well as annualized revenue data from 2013 and forecast to 2020.

This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GlobalData’s team of industry experts.

For more information, visit http://www.globaldata.com/QuotingGlobalData.aspx

About Globaldata
GlobalData is a leading global research and consulting firm offering advanced analytics to help clients make better, more informed decisions every day. Our research and analysis is based on the expert knowledge of over 700 qualified business analysts and 25,000 interviews conducted with industry insiders every year, enabling us to offer the most relevant, reliable and actionable strategic business intelligence available for a wide range of industries.

^*CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Brazil